N-乙烯基苯胺 | 6245-53-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-乙烯基苯胺
• 英文名称: phenylvinylamine
• 英文别名: N-vinylaniline；vinyl aniline；phenyl-vinyl-amine；N-ethenylaniline
• CAS: 6245-53-0
• 化学式: C₈H₉N
• mdl: MFCD19220671
• 分子量: 119.166
• InChiKey: PZUGJLOCXUNFLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-乙烯基苯胺 、 2-溴氯苯 在 lithium chloro-isopropyl-magnesium chloride 作用下， 以 四氢呋喃 为溶剂， -25.0~120.0 ℃ 、1.72 MPa 条件下， 反应 0.23h， 以44%的产率得到2-(allyl(phenyl)amino)phenol
  参考文献：
  名称：

  格氏试剂的需氧氧化连续流式合成功能化苯酚

  摘要：

  苯酚是化学工业中的重要化合物。描述了在连续的气液分段流系统中使用压缩空气通过直接氧化芳基格氏试剂来制备苯酚的一种经济，绿色的方法。该工艺可耐受各种官能团，包括对氧化敏感的官能团，例如烯烃，胺和硫醚。通过将苯并炔介导的芳基镁中间体的在线生成与好氧氧化相集成，建立了一种能够以模块化方式制备2-官能化苯酚的简便的三步单流方法。

  DOI：

  10.1002/anie.201310572

文献信息

• [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143144A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143143A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• ISOTHIOCYANATE PRODUCTION METHOD, COMPOSITION FOR TRANSPORTING AND STORING N-SUBSTITUTED O-SUBSTITUTED THIOCARBAMATE, AND ISOTHIOCYANATE COMPOSITION
  申请人：ASAHI KASEI CHEMICALS CORPORATION

  公开号：US20160016901A1

  公开（公告）日：2016-01-21

  The present invention relates to an isothiocyanate production method using an organic primary amine and thiourea as starting materials; to a composition for transporting and storing an N-substituted O-substituted thiocarbamate that includes an N-substituted O-substituted thiocarbamate and a hydroxy compound, the equivalent weight ratio of hydroxy groups of the hydroxy compound with respect to the carbamate groups of the N-substituted O-substituted thiocarbamate being in the range of 1 to 100; to a composition for transporting and storing a compound with a thioureido group that includes a compound with a thioureido group and a hydroxy compound, the equivalent weight ratio of hydroxy groups of the hydroxy compound with respect to the thioureido groups of the compound with a thioureido group being in the range of 1 to 100; and to an isothiocyanate composition containing an isothiocyanate and a compound with a specific functional group.

  该发明涉及一种使用有机初级胺和硫脲作为起始原料的异硫氰酸酯生产方法；一种用于运输和储存N-取代O-取代硫代氨基甲酸酯的组合物，包括N-取代O-取代硫代氨基甲酸酯和羟基化合物，羟基化合物的羟基与N-取代O-取代硫代氨基甲酸酯的羰基的当量重量比在1到100的范围内；一种用于运输和储存具有硫脲基团的化合物的组合物，包括具有硫脲基团的化合物和羟基化合物，羟基化合物的羟基与具有硫脲基团的化合物的硫脲基团的当量重量比在1到100的范围内；以及含有异硫氰酸酯和具有特定功能基团的化合物的异硫氰酸酯组合物。
• WATER-SOLUBLE FLUORO-SUBSTITUTED CYANINE DYES AS REACTIVE FLUORESCENCE LABELLING REAGENTS
  申请人：COOPER EDWARD MICHAEL

  公开号：US20060239922A1

  公开（公告）日：2006-10-26

  Disclosed are cyanine dyes that are useful for labelling and detecting biological and other materials. The dyes are of formula (I): in which at least one of groups R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 R 11 , R 12 , R 13 and R 14 is -L-M or -L-P, where L is a linking group, M is a target bonding group and P is a conjugated component, and at least one of groups R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 comprises fluorine. The use of cyanine dyes substituted by fluorine and having additional substitution with three or more sulphonic acid groups for labelling biological target molecules results in a labelled product in which there is reduced dye-dye aggregation and improved photostability, compared with cyanine dyes having no such substitutions. The dyes of the present invention are particularly useful in assays involving fluorescence detection where continual or repeated excitation is a requirement, for example in kinetic studies, or in microarray analyses where microarray slides may need to be reanalysed over a period of days.

  揭示了一种对于标记和检测生物和其他材料有用的青霉素染料。该染料的化学式为（I）：其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13和R14中的至少一个是-L-M或-L-P，其中L是连接基团，M是目标键合基团，P是共轭组分，并且R3、R4、R5、R6、R7、R8、R9和R10中的至少一个包含氟。通过用氟取代并具有三个或更多磺酸基团的青霉素染料标记生物靶分子，得到的标记产品中减少了染料-染料聚集并提高了光稳定性，与没有这种取代的青霉素染料相比。本发明的染料在涉及荧光检测的分析中特别有用，其中需要连续或重复激发，例如在动力学研究中，或在微阵列分析中，微阵列玻片可能需要在数天内重新分析。
• [EN] TETRAHYDROQUINOLINES AS AGONISTS OF LIVER-RECEPTORS<br/>[FR] TETRAHYDROQUINOLEINES UTILISEES COMME AGONISTES DES RECEPTEURS HEPATIQUES
  申请人：CARE X S A

  公开号：WO2004072041A1

  公开（公告）日：2004-08-26

  The present invention relates to specific compounds and pharmaceutically acceptable salts thereof; methods for synthesizing these compounds; compositions comprising at least one of these compounds or a pharmaceutically acceptable salt thereof; and methods for modulating liver-X receptors (LXRs) activity. The present invention further concerns methods for treating and/or preventing a disease or disorder selected from the group consisting of dyslipidemia, including hyperlipidemia, dyslipoproteinemia, including hyperlipoproteinemia, disorders related to cholesterol or bile acid metabolisms, including hypercholesterolemia, gall stone or gall bladder disorders, cardiovascular disease, including atherosclerotic cardiovascular diseases, coronary artery diseases, peripheral vascular diseases, cerebrovascular diseases, thrombotic disorders, restenosis or septic shock, CNS diseases including those affecting cognitive function or age related disorders such as Alzheimer's disease, Syndrome X, a liver-X receptor-associated disorder, obesity, pancreatitis, hypertension, renal disease, cancer, rheumatoid arthritis, inflammation, skin proliferative disorders, including psoriasis, atopic dermatitis or acne, and sexual impotence, comprising administering a therapeutically effective amount of a composition comprising at least one compound or a pharmaceutically acceptable salt thereof of the invention.

  本发明涉及特定化合物及其药用可接受盐；合成这些化合物的方法；包含至少一种这些化合物或其药用可接受盐的组合物；以及调节肝-X受体（LXRs）活性的方法。本发明还涉及治疗和/或预防以下疾病或疾病选择性群体中的疾病或紊乱的方法，包括脂质代谢异常，包括高脂血症，脂蛋白代谢异常，包括高脂蛋白血症，与胆固醇或胆汁酸代谢有关的紊乱，包括高胆固醇血症，胆结石或胆囊紊乱，心血管疾病，包括动脉粥样硬化心血管疾病，冠状动脉疾病，外周血管疾病，脑血管疾病，血栓性疾病，再狭窄或感染性休克，影响认知功能或与老年疾病如阿尔茨海默病、X综合征、肝-X受体相关疾病、肥胖、胰腺炎、高血压、肾脏疾病、癌症、类风湿性关节炎、炎症、皮肤增生性疾病，包括银屑病、特应性皮炎或痤疮，以及性功能障碍，包括给予本发明至少一种化合物或其药用可接受盐的组合物的治疗有效量。